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When adjusting for the same variables, QOL was higher in pts with
undetectable viremia (78.7±0.7% vs 74.0±1.58%; p=0.004), in males
(78.3±0.89% vs 74.5±1.39%; p=0.009), in MSMs vs heterosexuals vs others
[78.5±1.37% (p<0.0001) vs 77.2±1.33% (p=0.008) vs 73.3±1.07% (reference
group)], and also associated with age (b=-0.25, p<0.0001), current CD4+
(b=0.011, p<0.0001), and the number of pills (b=-0.77, p=0.019), but not
with dosing interval.
Conclusions: In this highly adherent population, adherence was not
associated with the number of daily pills or dosing interval. QOL was
associated with the pill burden, but the pill burden explained <1% of QOL.
Both adherence and QOL were strongly associated with virological response.
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Purpose of study: Recent treatment guidelines support the start of
antiretroviral treatment (ART) in HIV-infected persons already at a CD4-cell
count threshold 350 cells/μl. This includes to a large proportion
asymptomatic individuals who do not necessarily see a good reason to
start ART. In such cases, counselling can become a challenge. There is a
lack of structured tools to optimally assess patients’ readiness and to
support them in this process. The purpose of this project was twofold: First
to develop an algorithm for health care providers (HCP) to guide patients
in the situation of treatment start. Second to develop a workshop during
which HCP are instructed how to implement the algorithm and how to
improve communication skills.
Methods: Based on an action research approach, consecutively literature
review, own quantitative and qualitative studies and expert panel
discussions were performed. We developed an algorithm and piloted an
educational program for HCP. For this program critical incident reporting
by experienced HIV providers was used and usability was evaluated in
two workshops with HCP (self-reporting and group feedback).
Results: The readiness counselling algorithm has been integrated into
updated European guidelines (http://www.europeanaidsclinicalsociety.org/
guidelines.asp). It takes into account that patients are at different stages
of readiness to start ART and that there are barriers (e.g. depression)
before starting ART which have to be identified. An assessment of
patients’ actual stage of readiness and stage-based decision making
support is recommended. The pilot workshop uses techniques of patient-
oriented communication (waiting, echoing, mirroring, summarising) and a
video-based interaction module, in which HCP present individual patients
in whom the initiation of ART proved to be difficult. Re-playing these
short case vignettes gives all participants a chance to apply newly
acquired communication techniques. Participants rated these workshops
very positive, emphasizing the high degree of practicality, closeness to
their daily work, and usefulness of communication tools.
Conclusion: We developed an algorithm to assess and improve patients’
readiness to start ART and a corresponding workshop on the use of the
algorithm. Pilot workshops show that the algorithm is easy to implement
into daily practice, shows excellent acceptance and provides a basis for
the successful initiation of ART and long-term adherence to treatment.
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Background: The absence of detectable HIV resistance after treatment
failure may result from non-adherence, especially for drugs such as
ritonavir-boosted PIs (PI/r) for which minimum adherence may be
sufficient to achieve suppression. This analysis aimed to investigate the
association between adherence, indicated by a detectable PI plasma
concentration, and development of PI resistance in patients presenting
with virological failure of a PI/r regimen.
Methods: Patients were included if they had virologically failed a PI/r,
defined as a viral load (VL) >1000 copies/mL after ≥4 months continuous
exposure to a PI/r and with a plasma sample available within 1 month of
the estimated VL failure date. Samples were analysed for PI levels by a
validated reversed-phase HPLC method; an undetectable PI level was
defined as below the PI-specific lower limit of detection. Genotypic
sequencing was also carried out retrospectively on the identified sample
for those with no previous PI failure and PI resistance was defined as the
presence of ≥1 major PI mutation (IAS-USA). Logistic regression was used
to assess risk factors for an undetectable PI level and for detection of PI
resistance at VL failure using exact methods for small datasets.
Results: 85 patients were included. PI/r regimens were started in Sept
2002 (median) with VL failure occurring a median time of 17 months
later. At time of starting the PI/r (baseline), 57% were ARV-naïve, median
CD4 count was 217 cells/mm3 and median VL was 4.8 log10copies/mL. 43
patients (51%) had an undetectable PI level at time of VL failure and
were similar to those with detectable levels in terms of demographics,
ARV history and previous VL failure. However, injecting drug use was
associated with a greater risk of undetectable PI level (univariate odds
ratio (OR) IDU vs. not: 3.7; 95% CI: 1.1-12.5; p=0.038).
44 (52%) of the 85 patients were successfully tested for resistance and
had no previous PI failure. Those with undetectable PI levels were
significantly less likely to have PI resistance (0% of 24 patients, 95% CI: 0-
14%) than those with detectable levels (25% of 20, 95% CI: 9-49%), exact
median unbiased estimate of OR: 0.1; p=0.029. Baseline VL, CD4 count,
demographic and ARV-related variables were not associated with PI
resistance due to limited power in this dataset.
Conclusions: Non-adherence to a PI/r regimen, as measured by an
undetectable PI level is linked to a lower rate of detection of PI resistance
at time of VL failure.
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Purpose of the study: The purpose of the study was to analyze the
relationship between treatment adherence, quality of life and clinical
variables in HIV/AIDS infection.
Methods: Data was collected by voluntary fulfilment of three
questionnaires: one for socio-demographic variables, one to Assess
Adherence to Antiretroviral Treatment-HIV and the WHOQOL-Bref to
measure the quality of life (QoL). Clinical records were inspected in order
to collect clinical information from the patients. The relationship between
these variables was accessed by ANOVA using Tukey and LSD as the
post-hoc test. A 5% significance level was used.
Summary of results: The analysis was performed on a cohort of 295 HIV-
1 infected to ART individuals followed at the two Portuguese Hospitals
(Hospital de Joaquim Urbano and Curry Cabral). Median age was 40 years-
old, 64.4% were men. Median (range) TCD4+ cell count and viral load were
402 (238-620) cells/mm3 and 50 (20-50) cps/ml. Regarding disease stage,
the post-hoc analysis showed that asymptomatic patients have a better
level of adherence (p<0.001) and QoL (p=0.000) when compared to those
in more advanced stages of the disease. Undetectable viral load <20
copies/mL and T CD4+ cell count >500 cells/mm3 were also associated
with higher QoL (p=0.04 and p<0.001, respectively) and higher adherence
(p<0.001 and p<0.001, respectively). Patients on NRTI+NNTRI regimens
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have higher adherence when compared to those on NRTI+PI regimens
[72.4 (10.4) vs 69.1 (10.8); p=0.012] and higher QoL indexes [55.9 (20.1)] vs
49.6 (22.2); p<0.001]. When compared to twice daily regimens, patients on
single dose per day regimens have higher adherence [73.5 (9.6) vs 68.9
(11.2); p<0.001] and higher QoL [55.9 (20.1) vs 49.6 (22.2); p=0.001]. The
study also shows evidence of a positive and statistical association between
the adherence behavior and quality of life overall, with the highest
correlation found in the psychological domain (r=0.58, p<0.001) and the
lowest in the social relations (r=0.35, p<0.001) domain.
Patients experiencing adverse events have lower QoL [47.6 (22.2) vs 56.5
(20.0); p<0.001] and lower adherence levels [66.9 (11.3) vs 74.0 (9.3);
p<0.001] when compared to those not experiencing such events.
Conclusions: Both clinical variables and regimen characteristics were
found to be associated with adherence and QoL. These should thus be
considered when defining interventions to improve the adherence to the
antiretroviral therapy.
P120
Does feedback of medication execution using MEMS caps aid adherence
to HAART?: the MEMRI study (MEMS as Realistic Intervention)
S Davies1*, S Asghar1, V Cooper2, A Lange3, C Robertson1, B Vrijens3,
DJ White1
1Birmingham Heartlands Hospital, Birmingham, UK; 2The School of Pharmacy,
University of London, London, UK; 3Aardex Group Ltd., Sion, Switzerland
Journal of the International AIDS Society 2010, 13(Suppl 4):P120
Purpose of the study: Medication adherence is crucial for successful
Highly Active Antiretroviral Treatment (HAART). Adherence may be
divided into execution (how dosing history corresponds to the prescribed
drug dosing regimen) and persistence (the time from the first to last
taken dose). Medical Electronic Monitoring System (MEMS) monitors
record bottle opening events providing a graphical printout of
adherence. This can be used to provide positive feedback and correct
any perceptual inaccuracies as to adherence. MEMRI assesses the use of
such feedback as an intervention to support adherence. The primary
endpoint is based on execution.
Methods: 265 patients were recruited. 180 were suitable for randomisation.
All subjects were attending for HIV outpatients at Birmingham Heartlands
Hospital. MEMS cap data was available for analysis for 145 of these. 78
(Group A) were given regular feedback using graphical readouts by clinical
staff predominantly pharmacists. 67 (Group B) were blinded to feedback and
no graphical output was available. MEMS 6 monitors (LCD display) were
used on the most frequently dosed component of the HAART regimen.
MEMS were downloaded at each clinic visit. At time of this interim analysis
12 months of follow-up had been completed for all subjects.
Summary of results: 123 patients took qid regimens, 14 took bid
regimens, and 8 took multiple regimens during monitoring each divided
evenly between Group A and Group B. Medication execution was high in
both groups (>90%) for those patients who continued using the MEMS
cap. Feedback (Group A vs. B) was not associated with a significant
difference in execution but execution improved over time. There was a
larger drop-out rate in Group B vs. Group A (22 vs. 13 patients) although
this was not statistically significant. Execution was significantly worse at
weekends (p=0.0001).
Conclusions: A preliminary analysis of the MEMRI study primary endpoint
is presented. On limited follow-up at 12 months MEMS feedback showed
no effect on medication adherence but this was only on patients with
high initial adherence execution. This large adherence study includes a
wide range of patients and may be able to extrapolate to other groups.
Data based further follow-up will be presented and when complete the
study will include analysis of other factors such as perceived needs and
concern, self-efficacy and conscientiousness.
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Purpose of study: Even with the introduction of once daily antiretroviral
(ARV) regimens of low pill burden, long-term adherence remains a
challenge, particularly in subgroups, such as patients with drug addiction.
We aimed to determine levels of adherence and identify factors
associated with suboptimal adherence in treated, HIV-infected patients
attending a busy European inner-city HIV outpatient clinic.
Methods: In a prospective cohort study, adherence was assessed in HIV-
infected patients on antiretroviral therapy by self-report (ACTG adherence
questionnaire). Relationships between suboptimal adherence (defined as
<95%) and 49 covariates, including demographics, treatment factors,
Centre for Epidemiological Studies Depression (CES-D) score and
comorbidities were assessed using simple regression. Variables significant
(P < 0.05) in univariate analyses were evaluated using multivariate logistic
regression.
Results: 130 subjects (median [IQR] age 38 [11]; 27% female; 33% African
origin; 27% IDU, 30% heterosexual and 20% MSM) were recruited. 83%
were on once daily ARV and 16%, 34%, 48% and 2% were on regimens
comprising one, two, three and four ARV medications respectively.
Median CD4+ was 389 [285] cells/μL. 91% had HIV RNA < 50 copies/ml.
Median adherence was 92% [range 0-100%] and 28% had suboptimal
adherence. In univariate analyses, recent illicit drug use, on methadone,
higher CES-D score, taking a higher number of ARV medications, greater
pill burden, missed clinic appointments and lower CD4+ were associated
with suboptimal adherence. In multivariate analysis, missed clinic
appointments [OR 1.45; 95% CI (1.16, 1.81)] a higher CES-D score [OR
1.14; CI (1.01-1.28)] and being on a higher number of antiretroviral
medications [OR 3.45; CI (1.46, 8.54)] were all independent predictors of
suboptimal adherence.
Conclusions: In a cohort where many patients are on once daily ARV,
although attending clinic visits and psychological status remain
important, the number of antiretroviral medications is the strongest
independent predictor of adherence. Medication complexity (number of
ARV) rather than the pill burden is more predictive of poor adherence in
this cohort of patients from varied demographic backgrounds. Single pill,
fixed dose combinations (FDC) may improve adherence and these data
support further development of FDC especially for those with drug
addiction and psychological issues in which current FDC medications may
not be suitable.
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Purpose of the study: To estimate the short-term probability of
treatment change in antiretroviral naïve patients receiving tenofovir (TDF),
emtricitabine (FTC) and efavirenz (EFV) as a one (1p) or two pills (2p)
regimen.
Methods: We evaluated, by logistic regression and Cox proportional
model analysis, factors associated to treatment modification during the
first year of HAART in antiretroviral naïve patients from a single HIV unit
in Madrid who started treatment with TDF, FTC and EFV as 1 p or 2p. For
this analysis we censored patients who switched from 2p to 1p.
Results: From Jan/06 to Dec/09, 136 patients started HAART with TDF,
FTC & EFV as 1p (59, 42.8%) or 2p (79, 57.2%). Mean age: 38.5 (1p) and
38.6 (2p), 83.1% male (1p) and 75.3% (2p). Median CD4: 250 (1p) and 244
(2p), mean viral load (log): 4.53 (1p) and 4.48 (2p), HCV coinfected: 15.3%
(1p) and 19.5% (2p). One-year probability of HAART modification was
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